· Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024.

· Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.

· Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M).

.. Financial Performance

Fourth‑quarter IDEFIRIX product sales reached 61.1 MSEK, a 139% increase from 25.6 MSEK in Q4 2024. Revenue totalled 76.0 MSEK, representing a 135% increase compared to 32.3 MSEK in Q4 2024.

Full‑year 2025 IDEFIRIX product sales amounted to 204.7 MSEK for the full year, a 46% increase from 140.1 MSEK in the previous year. Revenue totalled 222.3 MSEK, representing a 30% increase compared to 171.3 MSEK in 2024. This growth reflects continued adoption across major European markets and underscores both the clinical value of IDEFIRIX, and the momentum Hansa is building in the treatment of highly sensitized patients undergoing kidney transplantation ..

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results | Hansa Biopharma

(www.hansabiopharma.com)